Active substance
Nicotinic acid
- US FDA 37
- US price lines 3
- Safety 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NIACOR | 500MG | tablet · oral | AVONDALE PHARMS | Prescription | 3 May 2000 |
| NIACIN | 1GM | tablet, extended release · oral | BARR | Prescription | 14 Apr 2005 |
| NIACIN | 500MG; 750MG | tablet, extended release · oral | BARR | Prescription | 26 Apr 2005 |
| NIACIN | 1GM | tablet, extended release · oral | CHARTWELL RX | Prescription | 20 Mar 2014 |
| NIACIN | 500MG | tablet, extended release · oral | CHARTWELL RX | Prescription | 20 Mar 2014 |
| NIACIN | 750MG | tablet, extended release · oral | CHARTWELL RX | Prescription | 20 Mar 2014 |
| NIACIN | 500MG; 1GM | tablet, extended release · oral | SUN PHARM | Prescription | 23 Apr 2014 |
| NIACIN | 750MG | tablet, extended release · oral | SUN PHARM | Prescription | 23 Apr 2014 |
| NIACIN | 500MG; 1GM | tablet, extended release · oral | AMNEAL PHARMS | Prescription | 24 Jul 2015 |
| NIACIN | 750MG | tablet, extended release · oral | AMNEAL PHARMS | Prescription | 11 Dec 2015 |
| NIACIN | 500MG; 1GM | tablet, extended release · oral | QUAGEN | Prescription | 16 Jun 2017 |
| NIACIN | 500MG; 750MG; 1GM | tablet, extended release · oral | AUROBINDO PHARMA LTD | Prescription | 1 Feb 2018 |
| NIACIN | 500MG; 1GM | tablet, extended release · oral | MACLEODS PHARMS | Prescription | 3 Mar 2022 |
| NIACIN | 500MG; 750MG; 1GM | tablet, extended release · oral | ADAPTIS | Prescription | 25 Aug 2023 |
| NIACIN | 500MG; 750MG; 1GM | tablet, extended release · oral | MPP PHARMA | Prescription | 25 Jul 2025 |
| WAMPOCAP | 500MG | capsule · oral | MEDPOINTE PHARM HLC | Discontinued | 24 Jul 1957 |
| NIACIN | 500MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 15 Sep 1972 |
| NIACIN | 500MG | tablet · oral | WATSON LABS | Discontinued | 4 Jan 1973 |
| NIACIN | 500MG | tablet · oral | MK LABS | Discontinued | 1 Aug 1973 |
| NIACIN | 500MG | tablet · oral | WATSON LABS | Discontinued | 10 Oct 1973 |
| NICOLAR | 500MG | tablet · oral | SANOFI AVENTIS US | Discontinued | 26 Nov 1973 |
| NIACIN | 500MG | tablet · oral | HIKMA | Discontinued | 7 Jan 1974 |
| NIACIN | 500MG | tablet · oral | WOCKHARDT | Discontinued | 28 Apr 1992 |
| NIASPAN | 375MG; 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, extended release · oral | ABBVIE | Discontinued | 28 Jul 1997 |
| NIASPAN TITRATION STARTER PACK | 375MG;500MG;750MG | tablet, extended release · oral | ABBVIE | Discontinued | 28 Jul 1997 |
12 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NIACIN ER 1,000 MG TABLET | $0.32626 | per EA | 23 Sep 2026 |
| US NADAC | NIACIN ER 500 MG TABLET | $0.19288 | per EA | 23 Sep 2026 |
| US NADAC | NIACIN ER 750 MG TABLET | $0.28483 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 2 May 2022 NIASPAN — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 May 2022 NIASPAN TITRATION STARTER PACK — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Nicotinic acid
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.